TEVA — TEVA PHARMACEUTICAL INDUSTRIES LTD

NYSE · Health Care · Pharmaceuticals · CIK 818686 · Israel
Last close
$33.21
Market Cap
$38.67B
52W High
$36.99
52W Low
$27.93
ADV30
5,977,093
Next earnings
2026-07-29
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,981,000,000 1,972,000,000 759,000,000 369,000,000 40,040,000,000 3,741,000,000 31,808,000,000
Dec 2025 4,711,000,000 2,656,000,000 1,269,000,000 480,000,000 40,748,000,000 3,556,000,000 32,834,000,000
Sep 2025 4,480,000,000 2,304,000,000 1,075,000,000 433,000,000 39,856,000,000 2,203,000,000 32,602,000,000
Jun 2025 4,176,000,000 2,102,000,000 899,000,000 282,000,000 40,131,000,000 2,161,000,000 33,297,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,714,000,000
Investing CF
$765,000,000
Financing CF
$-394,000,000
CapEx
$-542,000,000
Dividends Paid
Buybacks
EPS Diluted TTM
$1.33
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-13,394,000,000
Inventory
$3,176,000,000
Receivables
$3,393,000,000
ST Investments
EBIT TTM
$2,271,000,000
Pretax Income TTM
$1,366,000,000
Interest Exp TTM
$905,000,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$17,348,999,168
EBITDA
$5,002,999,808
Free Cash Flow
$2,611,375,104
Enterprise Value
$51,858,620,416
Total Cash
$3,740,999,936
Total Debt
$16,924,999,680
Shares Out
1,164,426,972
Trailing EPS
$1.34
Book Value
$7.07
ROE
21.6%
ROA
6.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 17,257,000,000 3,952,000,000 1,410,000,000 40,748,000,000 32,834,000,000 1,649,000,000
Dec 2024 16,544,000,000 3,364,000,000 -1,639,000,000 39,326,000,000 33,606,000,000 1,247,000,000
Dec 2023 15,845,000,000 3,194,000,000 -559,000,000 43,479,000,000 35,353,000,000 1,368,000,000
Dec 2022 14,925,000,000 2,690,000,000 -2,446,000,000 44,011,000,000 35,413,000,000 1,590,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$3.08

Max Pain — expiry 2026-06-26

max pain strike: $32.50 · spot: $34.22 · call oi: 4,780 · put oi: 933
Expected Move to 2026-06-26: ±$0.90 (2.63%) — implied range $33.32$35.12 · ATM straddle on $34.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALNY ALNYLAM PHARMACEUTICALS, INC. $38.48B $288.18
TEVJF TEVA PHARMACEUTICAL INDUSTRIES LTD $35.33B $30.34
ZTS Zoetis Inc. $32.21B $76.84
TKPHF TAKEDA PHARMACEUTICAL CO LTD $47.70B $30.19
TAK TAKEDA PHARMACEUTICAL CO LTD $50.05B $15.84

News headlines (Yahoo Finance, 1h cache)

Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?
2026-06-24 13:27 · Yahoo
Teva Pharmaceutical Industries (TEVA) Stock After 94% One-Year Surge Is The Price Justified
2026-06-24 03:28 · Yahoo
Is Ecopipam’s FDA Filing Reshaping the Investment Case For Teva Pharmaceutical Industries (TEVA)?
2026-06-23 17:16 · Yahoo
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
2026-06-23 15:44 · Yahoo
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
2026-06-23 13:58 · Yahoo
New Austedo Data Gives Teva (TEVA) Another Reason for Optimism
2026-06-22 13:31 · Yahoo
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
2026-06-19 13:16 · Yahoo
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
2026-06-19 12:56 · Yahoo
J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?
2026-06-19 12:07 · Yahoo
FDA Seeks Updated Labeling for Testosterone Therapies
2026-06-18 21:56 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.